Efficacy and Safety of Everolimus in Patients with Advanced Low- or Intermediate-grade Pancreatic Neuroendocrine Tumors Previously Treated with Chemotherapy: A Subgroup Analysis of the RADIANT-3 Trial

Rodney Pommier1; James Yao2; Timothy Hobday3; Eric Van Cutsem4; Edward Wolin5; Ashok Panneerselvam6; Ramon Castellana7; Sotirios Stergiopoulos7; Gaurav Shah8; Manisha Shah9; and Catherine Lombard-Bohas10

1Oregon Health and Science University, Portland, OR, USA; 
2Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 
3Departments of Internal Medicine and Oncology, Mayo Clinic, Rochester, MN, USA; 
4Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium; 
5Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 
6Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA; 
7Novartis Farmaceutics S.A., Barcelona, Spain; 
8Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 
9Ohio State University, Columbus, OH, USA; 
10Hôpital Edouard Herriot, Lyon, France

Background: Everolimus demonstrated significantly improved median progression-free survival (PFS) compared with placebo (11.0 vs 4.6 months; HR=0.35; P<0.0001) in patients with pancreatic neuroendocrine tumors (pNET) in the phase 3 RADIANT-3 trial. Results of the planned exploratory analysis by prior chemotherapy use are reported.

Methods: Patients with progressive low- or intermediate-grade pNET were prospectively stratified by prior chemotherapy use and randomized (1:1) to everolimus 10 mg/d (n=207) or placebo (n=203) plus best supportive care.

Results: Of 410 patients, 206 (50%) received prior chemotherapy and 204 (50%) were chemotherapy naive. Baseline characteristics (age, sex, race, tumor type, histologic grade) and baseline tumor biomarker levels were similar for patients with/without prior chemotherapy. More chemotherapy-naive patients were newly diagnosed (time since initial diagnosis ≤6 months; 50 [25%] vs 7 [3%] patients with prior chemotherapy). A lower proportion of chemotherapy-naive patients received prior somatostatin therapy (45% vs 54% with prior chemotherapy). Everolimus significantly prolonged median PFS versus placebo, regardless of prior chemotherapy use (with prior chemotherapy: 11.0 vs 3.2 months; HR=0.34; 95% CI, 0.25-0.48; P<0.001; chemotherapy naive: 11.4 vs 5.4 months; HR=0.42; 95% CI, 0.29-0.60; P<0.001). Irrespective of prior chemotherapy use, stable disease was the best overall response in 73% of everolimus-treated patients. The benefit from everolimus, irrespective of prior chemotherapy, was further demonstrated by disease stabilization or minor tumor shrinkage and the lower incidence of progressive disease in waterfall plots. The safety of everolimus was consistent regardless of prior chemotherapy use. The most common drug-related adverse events (prior chemotherapy vs chemotherapy naive) included rash (53% vs 52%), stomatitis (52% vs 56%), diarrhea (41% vs 52%), and fatigue (37% vs 51%).
Conclusions: This planned subgroup analysis demonstrated the beneficial effects of everolimus in patients with pNET, regardless of prior chemotherapy use. These findings support the possible first-line use of everolimus for patients with pNET.

Supported by Novartis Pharmaceuticals Corporation.